T2-weighted combined with diffusion-weighted images for evaluating prostatic transition zone tumors at 3 Tesla

Future Oncology

Volumn 9, Issue 4, 2013, Pages 585-593

  Ren, Jing ^a   Yang, Yong ^a   Zhang, Jinsong ^a   Xu, Jian ^a   Liu, Ying ^a   Wei, Mengqi ^a   Ge, Yali ^a   Huan, Yi ^a   Larson, Andrew C ^b   Zhang, Zhuoli ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

apparent diffusion coefficient; diffusion weighted imaging; imaging biomarker; MRI; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; CANCER SIZE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; T2 WEIGHTED NUCLEAR MAGNETIC RESONANCE IMAGING; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84875945846     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.14     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J. Clin. Oncol. 28(10), 1714-1720 (2010).
3. Bianco FJ Jr, Mchone BR, Wagner K, et al. Prevalence of erectile dysfunction in men screened for prostate cancer. Urology 74(1), 89-93 (2009).
4. Portalez D, Rollin G, Leandri P, et al. Prospective comparison of T2W-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur. Radiol. 20(12), 2781-2790 (2010).
5. De Visschere P, Oosterlinck W, De Meerleer G, Villeirs G. Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR 93(2), 62-70 (2010).
6. Grignon DJ, Sakr WA. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J. Cell. Biochem. Suppl. 19, 267-269 (1994). (Pubitemid 24306478)
7. Elliott CS, Shinghal R, Presti JC Jr. Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes. J. Urol. 180(4), 1318-1323; discussion 1323-1324 (2008).
8. Swindle P, Ramadan S, Stanwell P, McCredie S, Russell P, Mountford C. Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology. Magma 21(6), 423-434 (2008).
9. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78(2), 330-336 (1996). (Pubitemid 26234579)
10. Afaq A, Andreou A, Koh DM. Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging 10(10), S179-S188 (2010).
11. Jacobs MA, Ouwerkerk R, Petrowski K, Macura KJ. Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top. Magn. Reson. Imaging 19(6), 261-272 (2008).
12. Kim CK, Park BK, Park W, Kim SS. Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience. Abdom. Imaging 35(2), 246-252 (2010).
13. Kumar V, Jagannathan NR, Kumar R, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn. Reson. Imaging 24(5), 541-548 (2006). (Pubitemid 43776549)
14. Lee KC, Bradley DA, Hussain M, et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9(12), 1003-1011 (2007). (Pubitemid 350255347)
15. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection - a multireader study. Radiology 250(1), 145-151 (2009).
16. Charles-Edwards EM, Desouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 6, 135-143 (2006).
17. Fradet V, Kurhanewicz J, Cowan JE, et al. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology 256(1), 176-183 (2010).
18. De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am. J. Roentgenol. 194(6), 1427-1433 (2010).
19. Li H, Sugimura K, Kaji Y, et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am. J. Roentgenol. 186(3), 729-742 (2006). (Pubitemid 46100257)
20. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 239(3), 784-792 (2006). (Pubitemid 43830614)
21. Haider MA, Van Der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am. J. Roentgenol. 189(2), 323-328 (2007). (Pubitemid 47195916)
22. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest. Radiol. 41(2), 185-188 (2006). (Pubitemid 44406217)
23. Ohno Y, Hatabu H, Takenaka D, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology 231(3), 872-879 (2004). (Pubitemid 38668111)
24. Onishi Y, Ohno Y, Koyama H, et al. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Eur. J. Radiol. 79(3), 473-479 (2011).
25. Wang Z, Chang YC. Marker selection via maximizing the partial area under the ROC curve of linear risk scores. Biostatistics 12(2), 369-385 (2011).
26. Ellis JH, Tempany C, Sarin MS, Gatsonis C, Rifkin MD, McNeil BJ. MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. AJR Am. J. Roentgenol. 162(4), 865-872 (1994). (Pubitemid 24115872)
27. Kitajima K, Kaji Y, Fukabori Y, Yoshida K, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J. Magn. Reson. Imaging 31(3), 625-631 (2010).
28. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0 T. J. Magn. Reson. Imaging 23(2), 130-134 (2006). (Pubitemid 43191065)
29. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J. Magn. Reson. Imaging 28(3), 720-726 (2008).
30. Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MR imaging of the prostate in clinical practice. Magma 21(6), 379-392 (2008).